Search

Your search keyword '"Lutz, Catrin"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Lutz, Catrin" Remove constraint Author: "Lutz, Catrin"
35 results on '"Lutz, Catrin"'

Search Results

4. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

5. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers

6. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

7. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

8. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

11. Mechanisms that clear mutations drive field cancerization in mammary tissue

12. Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

13. The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

14. In situ CRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer

15. A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

16. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

17. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

18. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

19. Abstract 3488: Truncated FGFR2 - a clinically actionable oncogene in multiple cancers

20. Abstract PR006: A living biobank of patient-derived ductal carcinoma in situ (DCIS) Mouse-INtraDuctal (MIND) xenografts identifies multiple risk factors of invasive progression

23. Publisher Correction:Truncated FGFR2 is a clinically actionable oncogene in multiple cancers (Nature, (2022), 608, 7923, (609-617), 10.1038/s41586-022-05066-5)

24. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

25. Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

26. MYC promotes immune-suppression in TNBC via inhibition of IFN signaling

28. Truncated FGFR2is a clinically actionable oncogene in multiple cancers

29. In situCRISPR‐Cas9 base editing for the development of genetically engineered mouse models of breast cancer

31. Abstract A01: Somatic engineering of the mammary gland for the development of novel mouse models of triple-negative breast cancer

32. The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review

33. Publisher Correction: Truncated FGFR2is a clinically actionable oncogene in multiple cancers

34. The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells

35. The complex landscape of luminal breast cancer.

Catalog

Books, media, physical & digital resources